Holen Sie sich die Stockscreener-App
43.42
2.70%
1.14
Vorhandelsmarkt:
43.04
-0.38
-0.88%
Schlusskurs vom Vortag:
$42.28
Offen:
$42.49
24-Stunden-Volumen:
685.81K
Relative Volume:
0.83
Marktkapitalisierung:
$883.23M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-29.74
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
-2.41%
1M Leistung:
-20.84%
6M Leistung:
+70.07%
1J Leistung:
+4,418%
1-Tages-Spanne:
$41.51
$44.27
1-Wochen-Bereich:
$41.32
$44.40
52-Wochen-Spanne:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
43.42 | 860.04M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
FDA Leadership Stability Urged as Rare Disease Drug Approval Policies Expected to Show Results by 2026 - geneonline.com
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
What drives Nektar Therapeutics stock priceFinancial Sector Performance & Free Unlock Portfolio Growth - earlytimes.in
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Top 10 skin disorder stories of 2025 - Healio
Simplify Asset Management Inc. Buys 35,176 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Wrap: Why Nektar Therapeutics stock could rally in 2025Earnings Growth Summary & Risk Adjusted Buy/Sell Alerts - moha.gov.vn
Dermatology Times 2025 Year in Review: Atopic Dermatitis - Dermatology Times
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Brain Implants for Mental Health and Chinese Competition Expected to Shape BCI Advancements by 2026 - geneonline.com
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25% - simplywall.st
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Nektar Therapeutics (NKTR) CEO reports RSU and stock option grants - Stock Titan
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Earnings Miss Alerts & Maximize ROI With Proven Growth Stocks - Bollywood Helpline
Published on: 2025-12-23 18:23:01 - moha.gov.vn
Nektar Therapeutics announces phase 2b trial results - MSN
Atopic Dermatitis in 2025: Year in Review - HCPLive
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data - Benzinga
Transformative Advances This Year and Beyond - Dermatology Times
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) - Insider Monkey
Is Nektar Therapeutics (ITH0) stock ideal for retirement investors2025 Trading Volume Trends & Accurate Buy Signal Alerts - ulpravda.ru
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions - Seeking Alpha
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows - Yahoo Finance
Machine Learning Tool vConTACT3 Developed to Enhance Global Virus Classification - geneonline.com
Is Nektar Therapeutics stock resilient to inflationMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Why analysts remain bullish on Nektar Therapeutics stockMarket Rally & Reliable Price Breakout Signals - DonanımHaber
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Assessing Nektar Therapeutics (NKTR) Valuation After a Volatile Year and Recent Share Price Pullback - simplywall.st
Nektar Therapeutics Q3 2025 Earnings Preview - MSN
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Nektar Therapeutics announces top-line results from alopecia areata study - PMLiVE
Nektar Therapeutics Price Target Raised to $118.00/Share From $100.00 by BTIG - 富途牛牛
Nektar Therapeutics Is Maintained at Buy by BTIG - 富途牛牛
Nektar Therapeutics stock price target raised to $135 at H.C. Wainwright on alopecia data - Investing.com Nigeria
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg (NASDAQ:NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 6.5%Should You Sell? - MarketBeat
Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata - Patient Care Online
Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $121 - news.futunn.com
Nektar Therapeutics to Advance Rezpeg into Phase III Trials for Alopecia Areata Despite Phase II Endpoint Miss - geneonline.com
Nektar Therapeutics Earnings Notes - Trefis
BTIG Research Issues Positive Forecast for Nektar Therapeutics (NASDAQ:NKTR) Stock Price - MarketBeat
REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata - HCPLive
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg - BioSpace
Nektar reports positive Ph IIb results in alopecia areata - The Pharma Letter
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):